These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 36369798)
1. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Morand E; Pike M; Merrill JT; van Vollenhoven R; Werth VP; Hobar C; Delev N; Shah V; Sharkey B; Wegman T; Catlett I; Banerjee S; Singhal S Arthritis Rheumatol; 2023 Feb; 75(2):242-252. PubMed ID: 36369798 [TBL] [Abstract][Full Text] [Related]
2. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval. Loncharich MF; Anderson CW ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371 [TBL] [Abstract][Full Text] [Related]
3. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Furie RA; Morand EF; Bruce IN; Manzi S; Kalunian KC; Vital EM; Lawrence Ford T; Gupta R; Hiepe F; Santiago M; Brohawn PZ; Berglind A; Tummala R; Lancet Rheumatol; 2019 Dec; 1(4):e208-e219. PubMed ID: 38229377 [TBL] [Abstract][Full Text] [Related]
4. Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Isenberg D; Furie R; Jones NS; Guibord P; Galanter J; Lee C; McGregor A; Toth B; Rae J; Hwang O; Desai R; Lokku A; Ramamoorthi N; Hackney JA; Miranda P; de Souza VA; Jaller-Raad JJ; Maura Fernandes A; Garcia Salinas R; Chinn LW; Townsend MJ; Morimoto AM; Tuckwell K Arthritis Rheumatol; 2021 Oct; 73(10):1835-1846. PubMed ID: 34042314 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132. Burge DJ; Werth VP; Boackle SA; Posada J Lupus Sci Med; 2024 Feb; 11(1):. PubMed ID: 38325898 [TBL] [Abstract][Full Text] [Related]
6. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: Morand EF; Trasieva T; Berglind A; Illei GG; Tummala R Ann Rheum Dis; 2018 May; 77(5):706-713. PubMed ID: 29420200 [TBL] [Abstract][Full Text] [Related]
8. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. Morand EF; Furie R; Tanaka Y; Bruce IN; Askanase AD; Richez C; Bae SC; Brohawn PZ; Pineda L; Berglind A; Tummala R; N Engl J Med; 2020 Jan; 382(3):211-221. PubMed ID: 31851795 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial. Merrill JT; Tanaka Y; D'Cruz D; Vila-Rivera K; Siri D; Zeng X; Saxena A; Aringer M; D'Silva KM; Cheng L; Mohamed MF; Siovitz L; Bhatnagar S; Gaudreau MC; Doan TT; Friedman A Arthritis Rheumatol; 2024 Oct; 76(10):1518-1529. PubMed ID: 38923871 [TBL] [Abstract][Full Text] [Related]
10. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF; Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708 [TBL] [Abstract][Full Text] [Related]
11. What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials. Furie R; Morand EF; Bruce IN; Isenberg D; van Vollenhoven R; Abreu G; Pineda L; Tummala R Arthritis Rheumatol; 2021 Nov; 73(11):2059-2068. PubMed ID: 33913260 [TBL] [Abstract][Full Text] [Related]
12. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Khamashta M; Merrill JT; Werth VP; Furie R; Kalunian K; Illei GG; Drappa J; Wang L; Greth W; Ann Rheum Dis; 2016 Nov; 75(11):1909-1916. PubMed ID: 27009916 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial. Imafuku S; Tada Y; Hippeli L; Banerjee S; Morita A; Ohtsuki M J Dermatol; 2023 May; 50(5):588-595. PubMed ID: 36882942 [TBL] [Abstract][Full Text] [Related]
14. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Morand EF; Abreu G; Furie RA; Golder V; Tummala R Ann Rheum Dis; 2023 May; 82(5):639-645. PubMed ID: 36690388 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo-controlled trial in North East Asia. Suh CH; Lee Y; Yoo SB; Quasny H; Navarro Rojas AA; Hammer A; Song YW; Kang YM; Cho CS; Park W; Kwok SK; Lee SG; Chung WT; Bae SC Int J Rheum Dis; 2024 Jan; 27(1):e14997. PubMed ID: 38140854 [TBL] [Abstract][Full Text] [Related]
16. Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis. Cheng LE; Amoura Z; Cheah B; Hiepe F; Sullivan BA; Zhou L; Arnold GE; Tsuji WH; Merrill JT; Chung JB Arthritis Rheumatol; 2018 Jul; 70(7):1071-1076. PubMed ID: 29513931 [TBL] [Abstract][Full Text] [Related]
17. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. Ginzler E; Guedes Barbosa LS; D'Cruz D; Furie R; Maksimowicz-McKinnon K; Oates J; Santiago MB; Saxena A; Sheikh S; Bass DL; Burriss SW; Gilbride JA; Groark JG; Miller M; Pierce A; Roth DA; Ji B Arthritis Rheumatol; 2022 Jan; 74(1):112-123. PubMed ID: 34164944 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Wallace DJ; Strand V; Merrill JT; Popa S; Spindler AJ; Eimon A; Petri M; Smolen JS; Wajdula J; Christensen J; Li C; Diehl A; Vincent MS; Beebe J; Healey P; Sridharan S Ann Rheum Dis; 2017 Mar; 76(3):534-542. PubMed ID: 27672124 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Mease PJ; Deodhar AA; van der Heijde D; Behrens F; Kivitz AJ; Neal J; Kim J; Singhal S; Nowak M; Banerjee S Ann Rheum Dis; 2022 Jun; 81(6):815-822. PubMed ID: 35241426 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. Clowse ME; Wallace DJ; Furie RA; Petri MA; Pike MC; Leszczyński P; Neuwelt CM; Hobbs K; Keiserman M; Duca L; Kalunian KC; Galateanu C; Bongardt S; Stach C; Beaudot C; Kilgallen B; Gordon C; Arthritis Rheumatol; 2017 Feb; 69(2):362-375. PubMed ID: 27598855 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]